Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Phase 1 Trials

Fairfax, Virginia

Phase 1 colorectal cancer trials in Fairfax, VA

53 Phase 1 colorectal cancer studies are recruiting participants at sites in Fairfax as of November 17, 2026, according to ClinicalTrials.gov. Colorectal Phase 1 Trials can help you understand your options and connect with a study team.

Call (888) 415-5976
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Fairfax at a glance

  • 53 studies are recruiting at a site in Fairfax.
  • By phase: Phase 1 (28), Phase 1/2 (25).
  • By sponsor: industry (50), university, hospital or other (3).
  • Most recent update to one of these records: November 17, 2026.

Studies recruiting in Fairfax

Basic details from each study's public record (the 30 most recently updated of 53). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    NEXT Virginia
    Registry record
    NCT05786924 · updated
  2. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    NEXT Oncology - Virginia Cancer Specialists
    Registry record
    NCT06253871 · updated
  3. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study sites
    Inova Schar Cancer Institute · Virginia Cancer Specialists, PC
    Registry record
    NCT06324357 · updated
  4. A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Tyligand Pharmaceuticals (Suzhou) Limited
    Study site
    NEXT Virginia
    Registry record
    NCT06385925 · updated
  5. A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 to 99
    • All sexes
    Sponsor
    Erasca, Inc.
    Study site
    NEXT Virginia
    Registry record
    NCT06983743 · updated
  6. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Inova Schar Cancer Institute Clinical Trials
    Registry record
    NCT07488676 · updated
  7. A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    SOTIO Biotech a.s.
    Study site
    NEXT Virginia
    Registry record
    NCT07693751 · updated
  8. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Study sites
    Inova Schar Cancer Institute · NEXT Virginia
    Registry record
    NCT06270706 · updated
  9. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    NEXT Virginia
    Registry record
    NCT07458347 · updated
  10. A KRAS Inhibitor in Participants With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Ensem Therapeutics
    Registry record
    NCT07912593 · updated
  11. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT07020221 · updated
  12. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    NEXT Texas LLC - Virginia
    Registry record
    NCT07503808 · updated
  13. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    NEXT Virginia
    Registry record
    NCT07397338 · updated
  14. Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sairopa B.V.
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT05856981 · updated
  15. A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    NEXT Virginia, LLC
    Registry record
    NCT06720987 · updated
  16. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    NEXT Oncology Virginia
    Registry record
    NCT07542704 · updated
  17. A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    NEXT Virginia
    Registry record
    NCT07584226 · updated
  18. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Inc
    Study site
    NEXT Oncology Virginia
    Registry record
    NCT07094204 · updated
  19. A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Daiichi Sankyo
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT06330064 · updated
  20. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Alterome Therapeutics, Inc.
    Registry record
    NCT06835569 · updated
  21. Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sutro Biopharma, Inc.
    Study site
    NEXT Oncology Virginia
    Registry record
    NCT07807345 · updated
  22. Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BigHat Biosciences, Inc.
    Study site
    NEXT Virginia
    Registry record
    NCT07529808 · updated
  23. A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Arvinas Inc.
    Registry record
    NCT07749586 · updated
  24. AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Avacta Life Sciences Ltd
    Study site
    NEXT Oncology Virginia
    Registry record
    NCT07454642 · updated
  25. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT04585750 · updated
  26. A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    ALX Oncology Inc.
    Study site
    ALX Center 2
    Registry record
    NCT07085091 · updated
  27. A Study of PHN-012 in Patients With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pheon Therapeutics
    Study site
    PHN-012-001 Site
    Registry record
    NCT07127874 · updated
  28. Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Phanes Therapeutics
    Study site
    NEXT Oncology
    Registry record
    NCT05482893 · updated
  29. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    NEXT Oncology Virginia
    Registry record
    NCT06128551 · updated
  30. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT06445062 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Fairfax, VA on ClinicalTrials.gov.

Ask about studies near Fairfax

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Colorectal Phase 1 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 415-5976

or send a short form

How should we reach you?

Call